Patient demand and politics push Herceptin forward.

Reports on the decision of some Canadian provinces to pay for the extended use of trastuzumab or Herceptin in breast cancer treatment in 2005. Percentage of newly diagnosed breast cancer cases who are human epidermal growth factor receptor 2 positive; Number of provinces that have expanded funding for trastuzumab as of July 22, 2005; Comments from Sharon Batt, a breast cancer survivor and a Canadian Institutes of Health Research trainee in the ethics of health research and policy.